公司资料
BioVie Inc. 股价、新闻与催化剂
- 股票代码:
- BIVI
- 交易所:
- NASDAQ
- 行业:
- Biopharma
- 所在地:
- United States
股票表现
1.95 USD (+4.84%)
收盘价
最后更新: 2026年8月21日
12.8M USD
市值
股价为何变动
As of Aug 21, 2026, BIVI closed up 4.84% at $1.95. No new same-company headline was identified in the current news window.
公司概览
业务概览
BioVie is a biotechnology company focused on neurodegeneration, inflammation, and chronic disease biology. Its story has centered on trying to build a therapeutic platform in areas with large unmet need but high development risk.
所在地与行业分类
BioVie is headquartered in the United States and listed on NASDAQ. It sits in small-cap biotechnology.
商业模式特征
The company depends on clinical progress, strategic focus, and financing discipline. Investors usually watch early data, pipeline direction, and whether the company can preserve enough runway.
生物医药行业定位
BioVie occupies a speculative small-cap biotech niche. It is a catalyst-sensitive story where the market is still waiting for a clear clinical breakthrough.
未来催化剂
- BioVie’s catalysts are azeliragon-related programs and any strategic or clinical update that clarifies the company’s path. The next step matters because the company still needs a strong human-data signal.
近期新闻
- 01
- 02
- 03
- 04
- 05
相似股票
商业成熟度、治疗领域或催化剂模式相近的同行公司。